The latest study findings will be shared as they become available:
- Pre-existing antibody reactivity to SARS-CoV-2 is common in adults. Read the study:
A majority of uninfected adults show preexisting antibody reactivity against SARS-CoV-2
- Extending mRNA SARS-CoV-2 vaccine dosing intervals is particularly advantageous against the Delta variant. Read the study:
Immunogenicity of Extended mRNA SARS-CoV-2 Vaccine Dosing Intervals
- Most children with inflammatory bowel disease receiving anti-inflammatory anti-TNF medications respond well to two doses of the Pfizer COVID-19 mRNA vaccine. Read the study:
Antibody response to the BNT162b2 SARS-CoV-2 vaccine in paediatric patients with inflammatory bowel disease treated with anti-TNF therapy
Where can I learn more information about the study?
If you have questions after reading the study information, please email abcovid@bcchr.ca.